Compare Honeywell International Inc (HON) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Pfizer Inc — how do they compare? Honeywell International Inc trades at $208.63 (market cap $65.48B), while Pfizer Inc trades at $28.07 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 2.4× Honeywell International Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 90 Days and Pfizer Inc for 158 Days on average.
| HON | PFE | |
|---|---|---|
Market Cap | $65.48B | $158.56B |
Volume | 2,047,782 | 44,138,282 |
Sector | Industrials | Health |
52-Week High | $248.79 | $29.02 |
52-Week Low | $188.14 | $23.67 |
Typical Hold Time | 90 Days | 158 Days |
Enterprise Value | $90.27B | $210.06B |
Dividend Yield | 1.36% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $208.11, down 2.24% on the day, with a bearish technical signal from moving averages but strong fundamentals including a low P/E of 7.94 and robust ROE of 47.43%. Recent earnings beats and a $300 million refinery project win highlight operational strength, while the company's post-spin focus on automation drives growth expectations.
The outlook is positive with a consensus price target of $259.25 implying 24.6% upside, supported by analyst bullishness (66.7% buy ratings). Risks include rising debt-to-asset ratios and cyclical exposure, but solid cash flow and dividend payments provide stability amid near-term volatility.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
